Last Update: Aug 18, 2026 A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. ClinicalTrials.gov Identifier: [NCT05948943](https://clinicaltrials.gov/ct2/show/NCT05948943) Novartis Reference Number:CBYL719P12201 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo. This is a phase II/III multi-center study with two stages: \* Stage 1 is designed to select the dose(s) for the confirmatory phase (DSCP) for alpelisib in Stage 2 and will comprise a 24-week open-label core phase in adult (≥18 years of age) and pediatric participants (6-17 years of age) with PIK3CA-mutated LyM, followed by an extension. After eligibility has been confirmed at screening, participants will be randomized in a 1:1 ratio to the different alpelisib doses according to their age. Depending on the results at the end of Stage 1 core phase, the Stage 2 will be opened to adult and/or pediatric participants or the study may be stopped. \* Stage 2 is designed to confirm the efficacy and assess safety of alpelisib at the DSCP in participants with PIK3CA-mutated LyM and will comprise a 24-week randomized, double blind, placebo-controlled confirmatory phase in adult (≥18 years of age) and pediatric participants 6-17 years of age followed by an open-label extension. After eligibility has been confirmed at screening participants will be randomized in a 2:1 ratio to alpelisib or placebo. Additionally, in parallel, Stage 2 will include a 24-week open-label core phase in pediatric participants 0-5 years of age followed by an extension, if pediatric participants will be enrolling in Stage 2. Based on the results of the 24-week open-label core phase of Stage 1, the dose(s) for Stage 2 will be selected by Novartis in consultation with the Steering Committee (SC). During the 24-week randomized, double blind, placebo-controlled core phase of Stage 2, an Independent Data Monitoring Committee (DMC) will conduct periodic safety and efficacy reviews to assess the risk benefit profile of the treatment. Condition Lymphatic Malformations Phase Phase2, Phase3 Overall Status Recruiting Number of Participants232 Start Date Nov 24, 2023 Completion Date May 02, 2033 Gender All Age(s) 0 Years - 100 Years (Child, Adult, Older Adult) ## Interventions Drug ### Alpelisib In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib. In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 0-5 years of age will receive dose 3 of alpelisib Drug ### Placebo In Stage 2, participants will receive matching placebo for 24 weeks of the study ## Eligibility Criteria Key inclusion criteria: 1\. Signed informed consent and assent (when applicable) from the participant, parent, legal authorized representative or guardian. 2\. Participant must be willing to remain at the clinical site as required by the protocol and be willing to adhere to study restrictions and examination schedules. 3\. Participant has a physician confirmed and documented diagnosis of a symptomatic LyM at the time of informed consent (Note: the physician must confirm that the LyM cannot be included under the PROS diagnostic criteria). 4\. Participant is not considered as a candidate for or is not willing to receive non-drug therapies including but not limited to sclerotherapy, embolization, and surgery until the completion of Week 24 in Stage 1 and 2. 5\. Participant has evidence of a somatic mutation(s) in the PIK3CA gene prior to randomization. 6\. Participant has at least one measurable LyM lesion confirmed by BIRC assessment prior to randomization. 7\. Participants must be able to ingest study drug (either in tablet form or as a drinkable suspension \\\[Groups 1 to 4\\\] or granules or as an oral suspension \\\[Group 5\\\]) as assessed within 7 days before study treatment start. Drug administration via feeding tubes is allowed. Key exclusion criteria: 1\. Participant has a physician-confirmed and documented diagnosis of PROS at the time of informed consent. 2\. Participant has a physician-confirmed and documented diagnosis of a Central Conducting Lymphatic Anomaly, General Lymphatic Anomaly, Gorham-Stout disease, Kaposiform lymphangiomatosis at the time of informed consent. 3\. Participant has a known history of Stevens-Johnson syndrome, erythema multiforme, or toxic epidermal necrolysis at the time of informed consent. 4\. Participant has an established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus at the time of informed consent. 5\. Participant had previous treatment with alpelisib and/or any other PI3K inhibitors with treatment duration longer than 2 weeks at the time of informed consent. Other inclusion/exclusion criteria may apply Argentina #### Novartis Investigative Site Recruiting Capital Federal,C1023aab,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1425bea,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1181ach,Argentina Australia #### Novartis Investigative Site Recruiting Sydney,New South Wales,2010,Australia #### Novartis Investigative Site Recruiting Brisbane,Queensland,4101,Australia #### Novartis Investigative Site Recruiting Sydney,New South Wales,2031,Australia Belgium #### Novartis Investigative Site Recruiting Brussels,1200,Belgium Czechia #### Novartis Investigative Site Recruiting Brno,625 00,Czechia France #### Novartis Investigative Site Recruiting Paris,75015,France #### Novartis Investigative Site Recruiting Tours,37044,France #### Novartis Investigative Site Recruiting Paris,75010,France #### Novartis Investigative Site Recruiting Bron,69677,France #### Novartis Investigative Site Recruiting Bordeaux,33076,France #### Novartis Investigative Site Recruiting Toulouse,31054,France #### Novartis Investigative Site Recruiting Dijon,21000,France #### Novartis Investigative Site Recruiting Angers,49933,France #### Novartis Investigative Site Recruiting Montpellier,34295,France #### Novartis Investigative Site Recruiting Marseille,13885,France #### Novartis Investigative Site Recruiting Lille,59000,France #### Novartis Investigative Site Recruiting Caen,14033,France Germany #### Novartis Investigative Site Recruiting Berlin,13353,Germany #### Novartis Investigative Site Recruiting Cologne,North Rhine-Westphalia,50937,Germany #### Novartis Investigative Site Recruiting Ulm,89081,Germany #### Novartis Investigative Site Recruiting Leipzig,Saxony,04103,Germany #### Novartis Investigative Site Recruiting Freiburg im Breisgau,Baden-Wurttemberg,79106,Germany Italy #### Novartis Investigative Site Recruiting Roma,RM,00165,Italy #### Novartis Investigative Site Recruiting Torino,TO,10126,Italy #### Novartis Investigative Site Recruiting Roma,RM,00168,Italy #### Novartis Investigative Site Recruiting Bologna,BO,40138,Italy #### Novartis Investigative Site Recruiting Naples,80122,Italy #### Novartis Investigative Site Recruiting Milan,MI,20122,Italy Netherlands #### Novartis Investigative Site Recruiting Nijmegen,6525 ga,Netherlands #### Novartis Investigative Site Recruiting Rotterdam,South Holland,3015 gd,Netherlands Spain #### Novartis Investigative Site Recruiting Palma,Balearic Islands,07120,Spain #### Novartis Investigative Site Recruiting Madrid,28046,Spain #### Novartis Investigative Site Recruiting Barcelona,08035,Spain #### Novartis Investigative Site Recruiting L'Hospitalet de Llobregat,Barcelona,08907,Spain #### Novartis Investigative Site Recruiting Esplugues,Barcelona,08950,Spain #### Novartis Investigative Site Recruiting Madrid,28009,Spain #### Novartis Investigative Site Recruiting A Coruña,15006,Spain Switzerland #### Novartis Investigative Site Recruiting Lausanne,1011,Switzerland United Kingdom #### Novartis Investigative Site Recruiting London,Wc1n 3jh,United Kingdom United States #### Cinn Children Hosp Medical Center Recruiting Cincinnati,Ohio,45229-3039,United States ###### Adrienne Hammill ###### Sarah Price Phone: [513-636-6090](tel:513-636-6090) Email: #### Childrens Hosp Boston Dept of Heme Recruiting Boston,Massachusetts,02115,United States ###### Kelsey Deemer Phone: [617-355-5526](tel:617-355-5526) Email: ###### Tishi Shah #### UCSF Benioff Children s Hospital Recruiting Oakland,California,94609,United States ###### Sophie Shean Phone: [+1 510 428 3885 8227]() Email: ###### Beth Apsel Winger #### CHOP Abramson Pediatric Resch Ctr Recruiting Philadelphia,Pennsylvania,19104,United States ###### Melissa Casey Email: ###### Denise Adams #### Lucile Packard Childrens Hosp Recruiting Palo Alto,California,94304,United States ###### Thomas Buschbacher Email: ###### Joyce Teng #### Childrens Hospital and Regional Medical Center Recruiting Seattle,Washington,98105,United States ###### Maya Younoszai Phone: [206-526-2100](tel:206-526-2100) Email: ###### Jonathan A Perkins #### Childrens Hosp Pittsburgh UPMC Recruiting Pittsburgh,Pennsylvania,15224,United States ###### Julia Segal ###### Alex Berkebile Phone: [412-692-5346](tel:412-692-5346) Email: #### U of TX Health Science Ct Recruiting Houston,Texas,77030,United States ###### Kelly Mulligan Phone: [713-500-6852](tel:713-500-6852) Email: ###### Ionela Iacobas ###### Gaylon Stevenson Phone: [713-798-3701](tel:713-798-3701) Email: ###### Autumn Atkinson #### UNC Chapel Hill Recruiting Chapel Hill,North Carolina,27599,United States ###### Alexandra Borst ###### Miriam Davis Email: #### Childrens Hospital of Orange County Recruiting Orange,California,92868,United States ###### Eliud Espinal Phone: [714-509-8810](tel:714-509-8810) Email: ###### Maria Buethe #### Childrens National Medical Center Recruiting Washington D.C.,District of Columbia,20010-2970,United States ###### Yaser Diab ###### Regine Hyppolite Email: #### Univ Hospital Of Cleveland Recruiting Cleveland,Ohio,44106,United States ###### Erika Waites Phone: [216-844-7028](tel:216-844-7028) Email: ###### Howard Wang #### Cleveland Clinic Foundation Recruiting Cleveland,Ohio,44195,United States ###### Michael Kelly ###### Natalie Mau Email: #### Oregon Health Science University Recruiting Portland,Oregon,97239,United States ###### Melinda Wu ###### Annie Yang Email: #### WA Uni School Of Med Recruiting St Louis,Missouri,63110,United States ###### Bryan Sisk ###### Alison Barnwell Email: #### Nemours Childrens Clinic Recruiting Jacksonville,Florida,32207,United States ###### Anderson Collier ###### Rosita Almira Phone: [904-697-3674](tel:904-697-3674) Email: #### Nationwide Children s Hospital Recruiting Columbus,Ohio,43205,United States ###### Bhuvana Setty ###### Star Seum Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: